39 results
424B5
TLSA
Tiziana Life Sciences Ltd
1 Sep 23
Prospectus supplement for primary offering
5:16pm
and virtual research and development, or R&D, model using highly experienced teams of experts for each business function to maximize value accretion by focusing … expenses to increase in connection with our ongoing activities, particularly as we continue the R&D of, initiate further clinical trials of and seek
20-F/A
2022 FY
TLSA
Tiziana Life Sciences Ltd
13 Jun 23
Annual report (foreign) (amended)
12:37pm
movements
The Research and Development claim has been calculated in accordance with the R&D tax relief available to small and medium sized entities … periods relates to R&D tax relief claims for the prior period. Under UK tax legislation, a 2 year window is available under which R&D tax relief can
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
26 Apr 23
Report of Foreign Private Issuer
2:52pm
and development (R&D) expenses decreased to $13.0 million compared to $13.2 million in the twelve months ended 31 December 2021. The decrease is primarily
6-K
EX-99.1
TLSA
Tiziana Life Sciences Ltd
29 Dec 22
Updated Interim Results for the Six Months Ended 30 June 2022
6:15pm
ended the period with $26.5 million cash as of 30 June 2022 as compared to $42.2 million on 31 December 2021.
Research and development (R&D) expenses
6-K
EX-99.2
uj3sv7x9ikr8yfqi bz
29 Dec 22
Updated Interim Results for the Six Months Ended 30 June 2022
6:15pm
6-K
EX-99.1
1hlwu2c0df9ekrbrkgmi
27 Dec 22
Interim Results for the Six Months Ended 30 June 2022
5:49pm
6-K
EX-99.2
f48 qipumurs6
27 Dec 22
Interim Results for the Six Months Ended 30 June 2022
5:49pm
6-K
EX-99.1
qaca2dy 3pvo3tzwy8
18 Jul 22
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
6:04am
F-3/A
bmghn
25 Feb 22
Shelf registration (foreign) (amended)
4:10pm
6-K/A
EX-99.1
xlfa27
22 Feb 22
Interim Results for the Six Months Ended 30 June 2021
8:12am
F-3/A
a6jfct5c2fa6dy3 08q1
1 Feb 22
Shelf registration (foreign) (amended)
4:15pm
6-K
EX-99.1
rl7m8wwooa3lg2
24 Sep 21
Notes to the Interim Financial Statements
1:59pm
F-3
w0x8ukvegbpidj7lxl6p
26 Jan 21
Shelf registration (foreign)
5:31pm
6-K
EX-99.1
9q2ja0izzmkpm6b
13 Jan 21
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
6:02am
6-K
EX-99.2
hrjbz97v5 s9uzxkw
16 Sep 20
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, AccuStem Sciences
6:04am
424B5
ivyferp7 k26
4 Aug 20
Prospectus supplement for primary offering
4:35pm
6-K
EX-99.1
xu4zr9i9xfwcx
18 Jun 20
Final Results for the Year Ended 31 December 2019
7:01am